Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875

This article was originally published in The Gray Sheet

Executive Summary

EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.

You may also be interested in...



Urologix Doubles Presence In BPH Treatment Via $20 Mil. Prostatron Buy

Addition of Edap's Prostatron transurethral microwave thermotherapy (TUMT) system for treatment of benign prostatic hyperplasia (BPH) doubles Urologix' market presence in the BPH treatment area, the firm says. Urologix also expects the total number of cooled microwave thermotherapy procedures performed "to double in the next year" due to expanded market acceptance of the treatment.

Urologix Doubles Presence In BPH Treatment Via $20 Mil. Prostatron Buy

Addition of Edap's Prostatron transurethral microwave thermotherapy (TUMT) system for treatment of benign prostatic hyperplasia (BPH) doubles Urologix' market presence in the BPH treatment area, the firm says. Urologix also expects the total number of cooled microwave thermotherapy procedures performed "to double in the next year" due to expanded market acceptance of the treatment.

Urologix Shakes Off Reimbursement Woes; Stock Is Up Nearly 80% In July

Urologix' announcement that its Targis microwave system likely will be reimbursed on par with other minimally invasive therapies for benign prostatic hyperplasia under the Health Care Financing Administration's physician fee schedule signaled that the firm's payment problems may finally be coming to an end. The issue ended July up 78.5%.

Related Content

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel